Based on the advantages of heparin raw materials, extend and expand to downstream formulations

            Enhance the core competitiveness of the anticoagulant segmented market

Build well-known domestic and international brands of formulations

        In 2013, the company's board of directors proposed a development strategy that combines endogenous growth and outward expansion. Based on inheriting the advantages of existing heparin raw materials, the company expanded into new businesses in the formulation industry. In just nine months, Dongcheng Biopharmaceutical Industrial Park, as a platform for the development of formulation business, has emerged, laying a solid foundation for the enhancement of the company's core competitiveness.

The company has a rich pipeline of formulation products, with production lines for various dosage forms such as powder injections, tablets, capsules, granules, and drop pills. The products cover multiple therapeutic fields such as anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti infection. The company is based on the advantages of heparin raw materials and extends to downstream formulations. Currently, it has reserved multiple varieties of low molecular weight heparin formulations, laying the foundation for continuously building a well-known brand in the field of anticoagulation.